Myval is a novel balloon-expandable transcatheter heart valve that demonstrates favorable early safety, efficacy, and precise deployment for the treatment of severe aortic stenosis in observational studies.
Does the Myval transcatheter heart valve provide safe and effective treatment for patients with severe aortic stenosis?
The Myval transcatheter heart valve is a novel, balloon-expandable device with intermediate sizes that shows promising early clinical outcomes, including low rates of paravalvular leak and pacemaker implantation.
Transcatheter aortic valve implantation (TAVI) performed using femoral arterial access is now a guideline recommended treatment for severe calcific aortic stenosis (AS) in elderly patients. Technological advancements and procedural refinements have focused on making TAVI simpler, safer, more effective and durable. Myval (Meril Lifesciences) is a new generation balloon-expandable transcatheter heart valve (THV) developed in India that possesses novel features to improve deliverability and aid precise deployment. Following the first-in-human study, Myval was approved in India for commercial implantation in October 2018 and was subsequently given a CE mark in April 2019. This article reviews the science, technology and up-to-date clinical evidence for the Myval THV.
Seth et al. (Mon,) conducted a review in Severe calcific aortic stenosis. Myval transcatheter heart valve vs. Contemporary transcatheter heart valves (e.g., Sapien 3, Evolut R) was evaluated. Myval is a novel balloon-expandable transcatheter heart valve that demonstrates favorable early safety, efficacy, and precise deployment for the treatment of severe aortic stenosis in observational studies.